The covid-19 vaccine being developed by Pfizer and BioNTech is even more effective than previously thought.
The pharmaceutical companies have finished their Phase 3 study and say the jab has an efficacy rate of 95%.
That's 5% higher than what was announced last week.
Efficacy was consistent across age, gender, race and ethnicity demographics while no serious safety concerns were observed.
BREAKING: We are proud to announce, along with @BioNTech_Group, that the Phase 3 study of our #COVID19 vaccine candidate has met all primary efficacy endpoints.
— Pfizer Inc. (@pfizer) November 18, 2020
It's also met safety criteria - and will be submitted to US regulators for approval within days.
Ireland is set to get over 2.2 million doses of the vaccine if its approved for distribution, which would cover 1.1 million people.
Dr. Albert Bourla, Pfizer Chairman and CEO, says “With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world.”
